U.S. Markets open in 7 hrs 38 mins
  • S&P Futures

    3,449.50
    +0.25 (+0.01%)
     
  • Dow Futures

    28,272.00
    +4.00 (+0.01%)
     
  • Nasdaq Futures

    11,659.50
    +9.75 (+0.08%)
     
  • Russell 2000 Futures

    1,632.50
    +1.90 (+0.12%)
     
  • Crude Oil

    40.45
    -0.19 (-0.47%)
     
  • Gold

    1,907.60
    +3.00 (+0.16%)
     
  • Silver

    24.75
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1805
    -0.0021 (-0.1771%)
     
  • 10-Yr Bond

    0.8480
    0.0000 (0.00%)
     
  • Vix

    28.11
    -0.54 (-1.88%)
     
  • GBP/USD

    1.3060
    -0.0020 (-0.1515%)
     
  • USD/JPY

    104.6900
    -0.1500 (-0.1431%)
     
  • BTC-USD

    12,966.73
    0.00 (0.00%)
     
  • CMC Crypto 200

    261.78
    +5.68 (+2.22%)
     
  • FTSE 100

    5,785.65
    +9.15 (+0.16%)
     
  • Nikkei 225

    23,565.59
    +91.32 (+0.39%)
     

Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week

Entasis Therapeutics Holdings Inc.
·3 mins read

WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the company will have multiple data presentations at the virtual ID Week, being held October 21-25, 2020.

The details of the poster presentations include:

Sulbactam-durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical Isolates from the Middle East

Session Title:

Novel Agents

Poster Number:

1293

Presenting Author:

Alita Miller, Head of Bioscience, Entasis Therapeutics

Date:

Wednesday, October 21st

In Vitro Activity of Sulbactam-Durlobactam (ETX2514) Against Recent Global Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

Session Title:

Novel Agents

Poster Number:

1254

Presenting Author:

Alita Miller, Head of Bioscience, Entasis Therapeutics

Date:

Wednesday, October 21st

Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex – A Retrospective Review

Session Title:

Respiratory Infections – Bacterial

Poster Number:

1490

Presenting Author:

Khurram Rana, Director, Clinical Scientist, Entasis Therapeutics

Date:

Wednesday, October 21st

A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug-Resistant (MDR) Mycobacterium abscessus (Mab)

Session Title:

Tuberculosis and other Mycobacterial Infections

Poster Number:

1642

Presenting Author:

Khalid M. Dousa, Fellow, Case Western Reserve University

Date:

Wednesday, October 21st

All poster abstract presentations will be presented on-demand Wednesday, October 21, 2020.

About Entasis

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.

Entasis Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, changes in the regulatory environment, failure of Entasis’ collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Many of these factors are beyond Entasis’ control. These and other risks and uncertainties are described more fully in the Entasis’ filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Entasis Company Contact
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com

Investor Relations Contact
James Salierno
The Ruth Group
(646) 536-7028
jsalierno@theruthgroup.com

Media Contact
Kirsten Thomas
The Ruth Group
(508) 280-6592
kthomas@theruthgroup.com